Search Results - "BRAFFORD, Patricia"

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance by Shaffer, Sydney M., Dunagin, Margaret C., Torborg, Stefan R., Torre, Eduardo A., Emert, Benjamin, Krepler, Clemens, Beqiri, Marilda, Sproesser, Katrin, Brafford, Patricia A., Xiao, Min, Eggan, Elliott, Anastopoulos, Ioannis N., Vargas-Garcia, Cesar A., Singh, Abhyudai, Nathanson, Katherine L., Herlyn, Meenhard, Raj, Arjun

“…Through drug exposure, a rare, transient transcriptional program characterized by high levels of expression of known resistance drivers can get ‘burned in’,…”
Get full text

A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth by Roesch, Alexander, Fukunaga-Kalabis, Mizuho, Schmidt, Elizabeth C., Zabierowski, Susan E., Brafford, Patricia A., Vultur, Adina, Basu, Devraj, Gimotty, Phyllis, Vogt, Thomas, Herlyn, Meenhard

“…Melanomas are highly heterogeneous tumors, but the biological significance of their different subpopulations is not clear. Using the H3K4 demethylase JARID1B…”
Get full text

Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy by Somasundaram, Rajasekharan, Connelly, Thomas, Choi, Robin, Choi, Hyeree, Samarkina, Anastasia, Li, Ling, Gregorio, Elizabeth, Chen, Yeqing, Thakur, Rohit, Abdel-Mohsen, Mohamed, Beqiri, Marilda, Kiernan, Meaghan, Perego, Michela, Wang, Fang, Xiao, Min, Brafford, Patricia, Yang, Xue, Xu, Xiaowei, Secreto, Anthony, Danet-Desnoyers, Gwenn, Traum, Daniel, Kaestner, Klaus H., Huang, Alexander C., Hristova, Denitsa, Wang, Joshua, Fukunaga-Kalabis, Mizuho, Krepler, Clemens, Ping-Chen, Fang, Zhou, Xiangyang, Gutierrez, Alexis, Rebecca, Vito W., Vonteddu, Prashanthi, Dotiwala, Farokh, Bala, Shashi, Majumdar, Sonali, Dweep, Harsh, Wickramasinghe, Jayamanna, Kossenkov, Andrew V., Reyes-Arbujas, Jorge, Santiago, Kenisha, Nguyen, Tran, Griss, Johannes, Keeney, Frederick, Hayden, James, Gavin, Brian J., Weiner, David, Montaner, Luis J., Liu, Qin, Peiffer, Lukas, Becker, Jürgen, Burton, Elizabeth M., Davies, Michael A., Tetzlaff, Michael T., Muthumani, Kar, Wargo, Jennifer A., Gabrilovich, Dmitry, Herlyn, Meenhard

“…Anti-PD-1 therapy is used as a front-line treatment for many cancers, but mechanistic insight into this therapy resistance is still lacking. Here we generate a…”
Get full text

Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies by Krepler, Clemens, Xiao, Min, Sproesser, Katrin, Brafford, Patricia A, Shannan, Batool, Beqiri, Marilda, Liu, Qin, Xu, Wei, Garman, Bradley, Nathanson, Katherine L, Xu, Xiaowei, Karakousis, Giorgos C, Mills, Gordon B, Lu, Yiling, Ahmed, Tamer A, Poulikakos, Poulikos I, Caponigro, Giordano, Boehm, Markus, Peters, Malte, Schuchter, Lynn M, Weeraratna, Ashani T, Herlyn, Meenhard

“…To test second-line personalized medicine combination therapies, based on genomic and proteomic data, in patient-derived xenograft (PDX) models. We established…”
Get full text

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases by Smalley, Keiran S M, Haass, Nikolas K, Brafford, Patricia A, Lioni, Mercedes, Flaherty, Keith T, Herlyn, Meenhard

“…Although >66% of melanomas harbor activating mutations in BRAF and exhibit constitutive activity in the mitogen-activated protein kinase/extracellular…”
Get full text

ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma by Ndoye, Abibatou, Budina-Kolomets, Anna, Kugel, 3rd, Curtis H, Webster, Marie R, Kaur, Amanpreet, Behera, Reeti, Rebecca, Vito W, Li, Ling, Brafford, Patricia A, Liu, Qin, Gopal, Y N Vashisht, Davies, Michael A, Mills, Gordon B, Xu, Xiaowei, Wu, Hong, Herlyn, Meenhard, Nicastri, Michael C, Winkler, Jeffrey D, Soengas, Maria S, Amaravadi, Ravi K, Murphy, Maureen E, Weeraratna, Ashani T

“…Autophagy mediates resistance to various anticancer agents. In melanoma, resistance to targeted therapy has been linked to expression of Wnt5A, an intrinsic…”
Get full text

Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity by Zhang, Xue, Pant, Shishir M., Ritch, Cecily C., Tang, Hsin-Yao, Shao, Hongguang, Dweep, Harsh, Gong, Yao-Yu, Brooks, Rebekah, Brafford, Patricia, Wolpaw, Adam J., Lee, Yool, Weeraratna, Ashani, Sehgal, Amita, Herlyn, Meenhard, Kossenkov, Andrew, Speicher, David, Sorger, Peter K., Santagata, Sandro, Dang, Chi V.

“…The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role…”
Get full text

Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma by Fatkhutdinov, Nail, Sproesser, Katrin, Krepler, Clemens, Liu, Qin, Brafford, Patricia A, Herlyn, Meenhard, Aird, Katherine M, Zhang, Rugang

“…The majority of patients with melanoma harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However, response to mutant BRAF…”
Get full text

Epigenetic state determines inflammatory sensing in neuroblastoma by Wolpaw, Adam J, Grossmann, Liron D, Dessau, Jessica L, Dong, May M, Aaron, Bailey J, Brafford, Patricia A, Volgina, Darya, Pascual-Pasto, Guillem, Rodriguez-Garcia, Alba, Uzun, Yasin, Arsenian-Henriksson, Marie, Powell, Jr, Daniel J, Bosse, Kristopher R, Kossenkov, Andrew, Tan, Kai, Hogarty, Michael D, Maris, John M, Dang, Chi V

“…Immunotherapy has revolutionized cancer treatment, but many cancers are not impacted by currently available immunotherapeutic strategies. Here, we investigated…”
Get full text

PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas by Lee, John T., Li, Ling, Brafford, Patricia A., van den Eijnden, Marcia, Halloran, Molly B., Sproesser, Katrin, Haass, Nikolas K., Smalley, Keiran S.M., Tsai, James, Bollag, Gideon, Herlyn, Meenhard

“…Summary Targeted intervention of the B‐Raf V600E gene product that is prominent in melanoma has been met with modest success. Here, we characterize the…”
Get full text

Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma by Schäfer, Alexander, Haenig, Benedicte, Erupathil, Julie, Strickner, Panja, Sabato, Daniela, Welford, Richard W. D., Klaeylé, Lhéanna, Simon, Elise, Krepler, Clemens, Brafford, Patricia, Xiao, Min, Herlyn, Meenhard, Gstaiger, Matthias, Lehembre, Francois, Renz, Imke

“…The clinical benefit of MAPK pathway inhibition in melanoma patients carrying BRAF mutations is temporal. After the initial response to treatment, the majority…”
Get full text

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines by Garman, Bradley, Anastopoulos, Ioannis N., Krepler, Clemens, Brafford, Patricia, Sproesser, Katrin, Jiang, Yuchao, Wubbenhorst, Bradley, Amaravadi, Ravi, Bennett, Joseph, Beqiri, Marilda, Elder, David, Flaherty, Keith T., Frederick, Dennie T., Gangadhar, Tara C., Guarino, Michael, Hoon, David, Karakousis, Giorgos, Liu, Qin, Mitra, Nandita, Petrelli, Nicholas J., Schuchter, Lynn, Shannan, Batool, Shields, Carol L., Wargo, Jennifer, Wenz, Brandon, Wilson, Melissa A., Xiao, Min, Xu, Wei, Xu, Xaiowei, Yin, Xiangfan, Zhang, Nancy R., Davies, Michael A., Herlyn, Meenhard, Nathanson, Katherine L.

“…Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing of 108 genes previously implicated in melanomagenesis was…”
Get full text

MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer by Hew, Karina E, Miller, Philip C, El-Ashry, Dorraya, Sun, Jun, Besser, Alexandra H, Ince, Tan A, Gu, Mengnan, Wei, Zhi, Zhang, Gao, Brafford, Patricia, Gao, Wei, Lu, Yiling, Mills, Gordon B, Slingerland, Joyce M, Simpkins, Fiona

“…Although 67% of high-grade serous ovarian cancers (HGSOC) express the estrogen receptor (ER), most fail antiestrogen therapy. Because MAPK activation is…”
Get full text

Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes by PINNIX, Chelsea C, LEE, John T, YASHIRO-OHTANI, Yumi, NATHANSON, Katherine L, BENGSTON, Ana, POLLOCK, Pamela M, WEERARATNA, Ashani T, NICKOLOFF, Brian J, PEAR, Warren S, CAPOBIANCO, Anthony J, HERLYN, Meenhard, LIU, Zhao-Jun, MCDAID, Ronan, BALINT, Klara, BEVERLY, Levi J, BRAFFORD, Patricia A, MIN XIAO, HIMES, Benjamin, ZABIEROWSKI, Susan E

“…The importance of mitogen-activated protein kinase signaling in melanoma is underscored by the prevalence of activating mutations in N-Ras and B-Raf, yet…”
Get full text

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression by Liu, Zhao-Jun, Xiao, Min, Balint, Klara, Smalley, Keiran S M, Brafford, Patricia, Qiu, Ruihua, Pinnix, Chelsea C, Li, Xueli, Herlyn, Meenhard

“…Cellular signaling mediated by Notch receptors results in coordinated regulation of cell growth, survival, and differentiation. Aberrant Notch activation has…”
Get full text

Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells by Fang, Dong, Leishear, Kim, Nguyen, Thiennga K., Finko, Rena, Cai, Kun, Fukunaga, Mizuho, Li, Ling, Brafford, Patricia A., Kulp, Angela N., Xu, Xiaowei, Smalley, Keiran S. M., Herlyn, Meenhard

“…Because of their undifferentiated nature, human embryonic stem cells (hESCs) are an ideal model system for studying both normal human development and the…”
Get full text

Dysregulation of Claudin-7 Leads to Loss of E-Cadherin Expression and the Increased Invasion of Esophageal Squamous Cell Carcinoma Cells by Lioni, Mercedes, Brafford, Patricia, Andl, Claudia, Rustgi, Anil, El-Deiry, Wafik, Herlyn, Meenhard, Smalley, Keiran S.M

“…The claudins constitute a 24-member family of proteins that are critical for the function and formation of tight junctions. Here, we examine the expression of…”
Get full text

Selective evolutionary pressure from the tissue microenvironment drives tumor progression by Smalley, Keiran S.M., Brafford, Patricia A., Herlyn, Meenhard

“…Cells grow within defined environmental niches and are subject to microenvironmental control. Outside of their niche, the environment is hostile, the normal…”
Get full text

A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers by George, Erin, Kim, Hyoung, Krepler, Clemens, Wenz, Brandon, Makvandi, Mehran, Tanyi, Janos L., Brown, Eric, Zhang, Rugang, Brafford, Patricia, Jean, Stephanie, Mach, Robert H., Lu, Yiling, Mills, Gordon B., Herlyn, Meenhard, Morgan, Mark, Zhang, Xiaochen, Soslow, Robert, Drapkin, Ronny, Johnson, Neil, Zheng, Ying, Cotsarelis, George, Nathanson, Katherine L., Simpkins, Fiona

Get full text

Gene expression profiling of melanoma cells - searching the haystack by Brafford, Patricia, Herlyn, Meenhard

“…Cancer is being increasingly recognized as a very heterogeneous disease, both within an individual tumor and within a tumor type and among tumor types. This…”
Get full text